OPDIVO Qvantig™ permanent J-code available as of July 1, 2025

Posted on 08/20/2025

CMS has granted a unique J-code, J9289, for the use of OPDIVO Qvantig™ across all outpatient settings. J9289 is effective for dates of service on or after July 1, 2025. Bristol Myers Squibb would appreciate your partnership in updating systems and locations involved with the HCPCS and NDC information for J9289..

Learn More

The Different Colors of Skin Cancer Brochure

Posted on 07/22/2025

This brochure from Regeneron provides helpful information on advanced CSCC and advanced BCC in patients of color.

View Resource

Precision Medicine at J&J is working to advance cancer care across multiple diseases with biomarker-informed treatments in oncology.

Posted on 07/01/2025

Scan to visit our website and learn more: Here

Data rates may apply.

New XOFIGO® (radium-223 dichloride) Data in Metastatic Castration-Resistant Prostate Cancer from Phase III PEACE III Trial Published in Annals of Oncology

Posted on 06/09/2025

Annals of Oncology published full results from the pivotal investigational Phase III PEACE III trial, evaluating XOFIGO® (radium-223 dichloride) in combination with enzalutamide, an AR pathway inhibitor (ARPI), versus enzalutamide alone in the first-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases.

View Resource

Cancer of unknown primary (CUP): Implementation of a robust pathway

Posted on 05/27/2025

There is a need to improve upon the diagnostic strategies for cancer of unknown primary ​(CUP) tumors​. And reducing delays in diagnosis and identifying patients at earlier stages may potentially ​improve patient outcomes. These guides aim to highlight key considerations to take into account when establishing a robust CUP pathway in academic and community centers across the US​.

View First Resource View Second Resource

Jazz Pharmaceuticals Study for Adults Suffering from HER2-positive Biliary Tract Cancer

Posted on 05/14/2025

Jazz Pharmaceuticals is sponsoring a clinical study evaluating the safety and efficacy of an investigational medicine called zanidatamab for the treatment of advanced HER2-positive biliary tract cancer. Visit Biliary Tract Cancer Study - Inform Herizon BTC-302 Study - Jazz Pharmaceuticals or click the resource below to learn more.

View Resource

This Is Living With Cancer™

Posted on 04/24/2025

This Is Living With Cancer™ is a free online resource developed by Pfizer Oncology for all people living with cancer, regardless of age, income, race, location, cancer type, or stage of disease. This comprehensive program is available to anyone in the United States, whether they're on a Pfizer treatment or not, with a growing focus on those facing challenges accessing care.

Direct your patients to ThisIsLivingWithCancer.com to learn more.

View Resource

Anemia in Focus: The Challenge of Identifying Myelodysplastic Syndromes (MDS)

Published on: February 17, 2025

Watch Dr. David Sallman, a leading MDS specialist at the Moffitt Cancer Center, talk about the importance of investigating unexplained anemia.

View Resource Here

Centers for Medicare & Medicaid Services has assigned a permanent J-code for RYTELO

Posted on 1/16/2025

Consider updating your billing software to reflect the permanent J-code for RYTELO, J0870, and units: 1 unit per 1 mg, so J-code can be used on or after January 1, 2025.
View Resource

Genentech-Pro: Product, Access, and Disease State Resources for Providers & Patients

Posted on 12/28/2024

View Resource